Julia H Hayes

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis
    Julia H Hayes
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Institute for Clinical and Economic Review, Institute for Technology Assessment, Boston, MA 02115, USA
    Ann Intern Med 158:853-60. 2013
  2. ncbi request reprint Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective
    Julia H Hayes
    Diana Farber Cancer Institute, Center for Genitourinary Oncology, Massachusetts General Hospital, Boston, MA, USA
    BJU Int 100:486-8. 2007
  3. doi request reprint Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke
    Julia H Hayes
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    BJU Int 106:979-85. 2010
  4. pmc Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis
    Julia H Hayes
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    JAMA 304:2373-80. 2010
  5. doi request reprint Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death
    Toni K Choueiri
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 116:1887-92. 2010
  6. doi request reprint Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence
    Julia H Hayes
    Dana Farber Cancer Institute and Institute of Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    JAMA 311:1143-9. 2014
  7. doi request reprint Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medicine, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    BJU Int 110:1729-35. 2012

Collaborators

Detail Information

Publications7

  1. doi request reprint Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis
    Julia H Hayes
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Institute for Clinical and Economic Review, Institute for Technology Assessment, Boston, MA 02115, USA
    Ann Intern Med 158:853-60. 2013
    ..Observation is underutilized among men with localized, low-risk prostate cancer...
  2. ncbi request reprint Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective
    Julia H Hayes
    Diana Farber Cancer Institute, Center for Genitourinary Oncology, Massachusetts General Hospital, Boston, MA, USA
    BJU Int 100:486-8. 2007
  3. doi request reprint Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke
    Julia H Hayes
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    BJU Int 106:979-85. 2010
    ....
  4. pmc Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis
    Julia H Hayes
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    JAMA 304:2373-80. 2010
    ..Treatment of these cancers is associated with substantial morbidity. Active surveillance is an alternative to initial treatment, but long-term outcomes and effect on quality of life have not been well characterized...
  5. doi request reprint Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death
    Toni K Choueiri
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 116:1887-92. 2010
    ..BCR) as a time-dependent covariate (t) after radical prostatectomy (RP) for prostate cancer was associated with the risk of death and whether salvage therapy with radiotherapy (RT) and/or hormonal therapy (HT) can lessen this risk..
  6. doi request reprint Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence
    Julia H Hayes
    Dana Farber Cancer Institute and Institute of Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    JAMA 311:1143-9. 2014
    ..Prostate cancer screening with the prostate-specific antigen (PSA) test remains controversial...
  7. doi request reprint Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medicine, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    BJU Int 110:1729-35. 2012
    ....